Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $36.0 million.

  • Amylyx Pharmaceuticals' Operating Expenses fell 5264.4% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.7 million, marking a year-over-year decrease of 6656.71%. This contributed to the annual value of $402.1 million for FY2024, which is 1757.92% up from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Operating Expenses is $36.0 million, which was down 5264.4% from $42.9 million recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Operating Expenses peaked at $210.8 million during Q1 2024, and registered a low of $12.9 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $54.3 million (2022), whereas its average is $61.4 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Operating Expenses skyrocketed by 27157.29% in 2022, and later tumbled by 8206.46% in 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Operating Expenses (Quarter) stood at $28.3 million in 2021, then soared by 134.78% to $66.5 million in 2022, then surged by 60.23% to $106.5 million in 2023, then tumbled by 62.46% to $40.0 million in 2024, then fell by 9.91% to $36.0 million in 2025.
  • Its Operating Expenses stands at $36.0 million for Q3 2025, versus $42.9 million for Q2 2025 and $37.8 million for Q1 2025.